Lv3
207 积分 2023-10-09 加入
Combined oral PI3Kδ inhibitor linperlisib and HDAC inhibitor chidamide in relapsed/refractory peripheral T-cell lymphoma: a multicenter phase 1 trial
12小时前
已完结
PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial
13小时前
已完结
Allogeneic stem cell transplantation for major T-cell lymphoma entities: an analysis of the EBMT-lymphoma working party
7天前
已关闭
BiTE (CD3×EGFR)-Based Triplet Therapy Unlocks CD40/CD40L Crosstalk to Revert Immunosuppression in third-generation EGFR-TKI-Refractory NSCLC
7天前
已关闭
Electroacupuncture combined with fruquintinib and sintilimab in microsatellite-stable metastatic colorectal cancer: A phase II study
1个月前
已完结
Efficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphoma
1个月前
已完结
Targeting Class I Histone Deacetylases Triggers Antitumor Responses in Colorectal Cancer In Vitro and In Vivo
1个月前
已完结
INSR/AKT1 axis promotes cells proliferation and migration in acute myeloid leukemia
1个月前
已完结
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 study
1个月前
已完结
Recent advances and future perspectives in frontline treatment of peripheral T-cell lymphoma
1个月前
已完结
皖公网安备34019202002308
